

20 June 2017

Professor Robyn Ward  
Chair, Medical Services Advisory Committee  
Department of Health and Ageing  
MDP 851  
GPO Box 9848  
CANBERRA ACT 2601

Dear Professor Ward

**RE: Germline BRCA mutation testing to determine eligibility for Lynparza® (olaparib)**

Breast Cancer Network Australia (BCNA) is the peak national organisation for Australians personally affected by breast cancer. We support, inform, represent and connect people whose lives have been affected by breast cancer. BCNA represents more than 120,000 individual members and 300 Member Groups from across Australia.

This letter is to advise BCNA's support for an application to MSAC from AstraZeneca for germline BRCA mutation testing as a co-dependent service to determine eligibility for Lynparza treatment in women with locally advanced or metastatic breast cancer that is triple negative or HER2 negative or hormone receptor positive.

We understand that only patients who are germline BRCA mutation positive will be eligible for treatment with Lynparza.

BCNA believes that women who may be BRCA mutation positive and who may benefit from treatment with Lynparza should be able to access testing at an affordable price. The inclusion of BRCA mutation testing on the MBS for this purpose would help to make this test available to all women who could benefit from it.

Yours sincerely



Kathy Wells  
Head of Policy, Research and Advocacy